Immunization News and Research

RSS

HHS joins with Ad Council to launch new nationwide PSA campaign

HHS Secretary Kathleen Sebelius announced today that the U.S. Department of Health and Human Services (HHS) is joining with the Ad Council to launch a new nationwide public service advertising (PSA) campaign called “Together We Can All Fight the Flu.”

7 Dec 2009

Measles deaths decline worldwide by 78%, experts warn against complacency

Measles deaths fell from 733,000 in 2000 to 164,000 in 2008 - 78 percent - thanks, in part, to increased vaccination efforts that reached an estimated 700 million children, according to a report released Thursday by the U.S.-based Measles Initiative, Reuters reports.

4 Dec 2009

Study reveals that majority of all vaccine preventable deaths occur in those 65 and older

Ninety percent of all vaccine preventable deaths occur in those 65 and older, including residents in nursing homes, according to highlighted studies in the Pennsylvania Patient Safety Authority's 2009 December Patient Safety Advisory.

4 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections.

3 Dec 2009

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).

3 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

Respiratory syncytial virus, the most common cause of pneumonia in children

RSV is a respiratory virus that infects the lungs and breathing passages. While most healthy people recover from RSV infection, it can be severe in infants. According to the United States Centers for Disease Control and Prevention (CDC), RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the nation.

3 Dec 2009

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City.

1 Dec 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

Melvin R. Kaplan to be honored for his lifetime devotion to the care of patients

Melvin R. Kaplan, MD, FACP, a former Board Chair and one of the founders of the research institute that became Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), will be honored by the American College of Physicians for his lifetime devotion to the care of patients.

26 Nov 2009

Americans with hepatitis C are at increased risk of developing liver cancer, says NVHR

New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti-viral therapy in recent years should be a wake-up call that Congress needs to move urgently on bipartisan legislation to support new state-based detection, research, and surveillance efforts, the National Viral Hepatitis Roundtable (NVHR) said today.

24 Nov 2009

Walgreens re-launches its website with expanded shopping tools and services

Walgreens, the nation’s largest drugstore chain and a leading destination for health and wellness services, today announced the re-launch of Walgreens.com (www.walgreens.com), offering users a variety of new healthy living and product resources, along with expanded yet simplified shopping tools and services.

23 Nov 2009

CDC: 'Beggining to see some declines in swine flu'

Reuters: "The pandemic of swine flu may be hitting a peak in the United States, health experts said on Friday. But they stressed that influenza, especially a pandemic, could hit several peaks in a single season. They said weeks or months more of disease could be expected.

23 Nov 2009

Three health care organizations implement interconnected EHR system

Three of the largest Front Range health care organizations are taking an unprecedented leap forward in health care reform by improving care for more than a million Coloradans with an interconnected electronic patient record exchange system.

21 Nov 2009

LAIV and TIV vaccines appear to offer protection against A/H1N1 virus

Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.

20 Nov 2009

Washington Global Health Alliance completes internal coordination study of global health

The Washington Global Health Alliance, a group representing 26 life-sciences businesses, institutions and governmental organizations, has completed an internal coordination study demonstrating the significant influence of its primary partners in the mission of global health.

19 Nov 2009

FDA Advisory Committee votes in support of Pfizer's Prevnar 13

Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children.

19 Nov 2009

Tips for lessening needle anxiety

Experts believe fear of needles may be preventing people from rolling up their sleeves for the H1N1 vaccination.

18 Nov 2009

Pentavalent price drops: the GAVI effect

Following the increasing impact of the GAVI Alliance on the vaccine market, the price of one of the major combination vaccines, the pentavalent, is falling considerably, enabling GAVI’s partners to vaccinate millions of more children in the developing world.

18 Nov 2009

Immunization News and Research

HHS joins with Ad Council to launch new nationwide PSA campaign

Measles deaths decline worldwide by 78%, experts warn against complacency

Study reveals that majority of all vaccine preventable deaths occur in those 65 and older

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

Respiratory syncytial virus, the most common cause of pneumonia in children

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Melvin R. Kaplan to be honored for his lifetime devotion to the care of patients

Americans with hepatitis C are at increased risk of developing liver cancer, says NVHR

Walgreens re-launches its website with expanded shopping tools and services

CDC: 'Beggining to see some declines in swine flu'

Three health care organizations implement interconnected EHR system

LAIV and TIV vaccines appear to offer protection against A/H1N1 virus

Washington Global Health Alliance completes internal coordination study of global health

FDA Advisory Committee votes in support of Pfizer's Prevnar 13

Tips for lessening needle anxiety

Pentavalent price drops: the GAVI effect

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News